Journal of Affective Disorders
Volume 85, Issue 3 , Pages 333-339 , April 2005

Do venlafaxine XR and paroxetine equally influence negative and positive affect?

  • Gabriel S. Dichter

      Affiliations

    • Department of Psychology, College of Arts and Sciences, Wilson Hall, Vanderbilt University, Nashville TN 37203, United States
    • ,
  • Andrew J. Tomarken

      Affiliations

    • Department of Psychology, College of Arts and Sciences, Wilson Hall, Vanderbilt University, Nashville TN 37203, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 615 322 4177; fax: +1 615 343 8449.
    • ,
  • Cathryn M. Freid

      Affiliations

    • Department of Psychology, College of Arts and Sciences, Wilson Hall, Vanderbilt University, Nashville TN 37203, United States
    • ,
  • Stephanie Addington

      Affiliations

    • Department of Psychiatry, Vanderbilt University Medical Center, Nashville TN, United States
    • ,
  • Richard C. Shelton

      Affiliations

    • Department of Psychiatry, Vanderbilt University Medical Center, Nashville TN, United States

Received 23 October 2003 ,Revised 24 September 2004 ,Accepted 6 October 2004.

References 

  1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. DSM-IV. 4th ed.. Washington, DC: American Psychiatric Association; 1994;
  2. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J. Consult. Clin. Psychol. 1988;56(6):893–897
  3. Beck AT, Steer RA, Brown GK. Manual for Beck Depression Inventory—II. San Antonio, TX: Psychological; 1996;
  4. Bodkin JA, Lasser RA, Wines JD, Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J. Clin. Psychiatry. 1997;58(4):137–145
  5. Bryk AS, Raudenbush SW. Hierarchical Linear Models: Applications and Data Analysis Methods. Newbury Park: Sage Publications; 1992;
  6. Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J. Abnorm. Psychology. 1991;100(3):316–336
  7. Clinical Global Impressions, 1976. In: W. Guy (Ed.), ECDEU Assessment Manual for Psychopharmacology Review (pp. 217–222). Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch: U.S. National Institute of Health, Early Clinical Drug Evaluation, Psychopharmacology Research Branch.
  8. Depue RA, Collins P. Neurobiology of the structure of personality: dopamine, facilitation of incentive motivation, and extraversion. Behav. Brain Sci. 1999;22:491–569
  9. Depue RA, Spoont MR. Conceptualizing a serotonin trait. A behavioral dimension of constraint. Ann. N.Y. Acad. Sci. 1986;487:47–62
  10. Depue RA, Luciana M, Arbisi P, Collins P, Leon A. Dopamine and the structure of personality: relation of agonist-induced dopamine activity to positive emotionality. J. Pers. Soc. Psychol. 1994;67(3):485–498
  11. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P). Washington, DC: American Psychiatric Press; 1997;
  12. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch. Gen. Psychiatry. 1993;50(9):739–750
  13. Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am. J. Psychiatry. 2002;159(10):1702–1710
  14. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 1959;32:50–55
  15. Hamilton MA. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960;23:56–62
  16. Karson CN, Kleinman JE, Berman KF, Phelps BH, Wise CD, DeLisi LE, et al. An inverse correlation between spontaneous eye-blink rate and platelet monoamine oxidase activity. Br. J. Psychiatry. 1983;142:43–46
  17. Knutson B, Wolkowitz OM, Cole SW, Chan T, Moore EA, Johnson RC, et al. Selective alteration of personality and social behavior by serotonergic intervention. Am. J. Psychiatry. 1998;155(3):373–379
  18. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Publishing; 1996;
  19. Maj J, Rogoz Z. Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine and serotonin systems. J. Neural Transm. 1999;106(2):197–211
  20. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 1986;35(24):4493–4497
  21. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 1997;283(3):1305–1322
  22. Reist C, Helmeste D, Albers L, Chhay H, Tang SW. Serotonin indices and impulsivity in normal volunteers. Psychiatry Res. 1996;60(2–3):177–184
  23. Rudolph RL. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. Acta Psychiatr. Scand., Suppl. 2002;415:24–30
  24. Shelton R, Brown L. Mechanisms of action in the treatment of anxiety. J. Clin. Psychiatry. 2000;62(Suppl. 12):10–15
  25. Shelton RC, Tomarken AJ. Can recovery from depression be achieved?. Psychiatr. Serv. 2001;52(11):1469–1478
  26. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol. Psychiatry. 2002;52(12):1166–1174
  27. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry. 2001;178:234–241
  28. Tomarken AJ, Shelton RC, Elkins L, Anderson T. Sleep deprivation and anti-depressant medication: unique effects on positive and negative affect. In: Paper presented at the American Psychological Society Meeting, Washington, DC. 1997;
  29. Tomarken AJ, Dichter GS, Freid C, Addington S, Shelton RC. Assessing the effects of bupropion SR on mood dimensions of depression. J. Affect. Disord. 2004;78(3):235–241
  30. van Praag HM, Kahn R, Asnis GM, Lemus CZ, Brown SL. Therapeutic indications for serotonin-potentiating compounds: a hypothesis. Biol. Psychiatry. 1987;22(2):205–212
  31. Watson D, Clark LA, Weber K, Assenheimer JS, Strauss ME, McCormick RA. Testing a tripartite model: II. Exploring the symptom structure of anxiety and depression in student, adult, and patient samples. J. Abnorm. Psychol. 1995;104(1):15–25
  32. Watson D, Weber K, Assenheimer JS, Clark LA, Strauss ME, McCormick RA. Testing a tripartite model: I. Evaluating the convergent and discriminant validity of anxiety and depression symptom scales. J. Abnorm. Psychol. 1995;104(1):3–14
  33. Zald D, Depue RA. Serotonergic functioning correlates with positive and negative affect in psychiatrically healthy males. Pers. Individ. Differ. 2001;30:71–86

PII: S0165-0327(04)00370-2

doi: 10.1016/j.jad.2004.10.007

Journal of Affective Disorders
Volume 85, Issue 3 , Pages 333-339 , April 2005

Article Tools

* Image Usage & Resolution